SRF Limited — Investor Meet, 28-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

SRF reported Q3 FY26 gross revenue up 6% YoY to ₹3,713 Cr. EBIT grew 23% to ₹653 Cr (18% margin), with PAT surging 60% to ₹433 Cr. Chemicals revenue rose 22% to ₹1,825 Cr. A second interim dividend of ₹5/share was approved.

Management notes resilience in a challenging market. Specialty Chemicals faced Chinese pricing pressure, but Q4 is expected to improve from deferred orders and a robust pipeline, including a new ₹180 Cr pharma intermediate plant. Fluorochemicals achieved a record quarter driven by firm HFC prices and recovering domestic demand, optimizing production under the Kigali framework. Performance Films saw domestic recovery and BOPET price improvement from Chinese capacity cuts.

SRF focuses on R&D, pharma diversification, and value-added products. Strategic investments like the Odisha site for next-gen refrigerant gases are on track. Management is confident about sustainable growth and long-term value creation despite current global volatility, with an optimistic outlook on market recovery and strategic execution.